Reformulation of study drug to help reduce the pill burden as higher doses are evaluated.

This is an open label, non-randomized, Phase I, dose escalation/dose expansion study of PCUR-101 in combination with androgen suppression therapy in the patients with metastatic CRPC

Inclusion Criteria:

• histologically confirmed diagnosis of metastatic CRPC
• standard of care androgen deprivation treatment
• castrate serum level of testosterone of ≤ 50 ng/dL (≤ 1.73 mmol/L)
• progressive disease while receiving androgen deprivation therapy
• previously treated with abiraterone, enzalutamide alone or in combination AND must have demonstrated evidence of objective progression as per PCWG3 criteria
• adequate hematologic, renal and hepatic function
• KPS of ≥ 70 or ECOG of 0 to 1

Exclusion Criteria:

• pure small cell, neuroendocrine or other variant (non-adenocarcinoma) prostate cancer histology
• use of opiate analgesics for prostate cancer pain within 4 week of treatment start
• more than one sequential second generation AR-directed therapy
• received cytotoxic chemotherapy for either metastatic HSPC or CRPC within the last 12 weeks or other investigational agents within 4 weeks
• history of bleeding disorder
• history of seizure disorder
• concomitant use of therapeutic anticoagulation
• history of or current cardiac issues
• received external beam radiation therapy within 4 weeks
• CTCAE Grade > 2 neuropathy